Department of Preclinical and Clinical Pharmacology, Viale G. Pieraccini 6, 50139 Florence, Italy.
Neuropharmacology. 2012 Jan;62(1):289-96. doi: 10.1016/j.neuropharm.2011.07.020. Epub 2011 Jul 22.
We investigated the involvement of extracellular signal-regulated kinase (ERK), c-Jun-N-terminal kinase/stress-activated protein kinase (JNK/SAPK), p38MAPK pathways, and the upstream modulator protein kinase C (PKC) in the antidepressant activity of amitriptyline. Mice were exposed to the forced swimming test (FST) that increased the phosphorylation of PKCɛ, ERK1, ERK2, JNK-s and p38MAPK in the hippocampus. A differential pattern of activation was observed in the frontal cortex where FST selectively increased PKCɛ, ERK2, JNK-l and JNK-s. Acute administration of amitriptyline (10 mg kg(-1) i.p.) left unchanged p-ERK1 and p-ERK2 levels whereas prevented the phosphorylation of PKCɛ and p38MAPK. Pretreatment with the PKC blocker calphostin C (0.1 μg i.c.v.) prevented this increased hippocampal phosphorylation of p38MAPK. Behavioural experiments showed that the administration of the p38MAPK inhibitor SB203580 (5-10 μg i.c.v.) and calphostin C produced an antidepressant-like phenotype without altering the spontaneous locomotor activity. An intensive JNK phosphorylation was observed in the frontal cortex of animals exposed to FST, effect that was further potentiated by acute administration of amitriptyline. No modulation on the cAMP response element-binding protein (CREB) phosphorylation and expression was observed in the hippocampus and frontal cortex of amitriptyline-treated mice. Present results illustrate a selective modulation of PKCɛ and p38MAPK phosphorylation after acute administration of amitriptyline in mice exposed to FST, identifying the PKCɛ/p38MAPK signalling cascade an essential step in the acute antidepressant-like activity of amitriptyline. We also demonstrated a potentiation of the JNK phosphorylation in the frontal cortex by amitriptyline that might represent a pathway of negative modulation of antidepressant properties. This article is part of a Special Issue entitled 'Anxiety and Depression'.
我们研究了细胞外信号调节激酶(ERK)、c-Jun-N-末端激酶/应激激活蛋白激酶(JNK/SAPK)、p38MAPK 通路以及蛋白激酶 C(PKC)上游调节剂在阿米替林抗抑郁活性中的作用。将小鼠暴露于强迫游泳试验(FST)中,增加了海马体中 PKCɛ、ERK1、ERK2、JNK-s 和 p38MAPK 的磷酸化。在前额叶皮层中观察到了不同的激活模式,其中 FST 选择性地增加了 PKCɛ、ERK2、JNK-l 和 JNK-s。急性给予阿米替林(10mg/kg,腹腔注射)未改变 p-ERK1 和 p-ERK2 水平,但可防止 PKCɛ 和 p38MAPK 的磷酸化。预先给予 PKC 阻滞剂钙泊三醇 C(0.1μg,脑室内注射)可防止 p38MAPK 在此处的海马体磷酸化增加。行为学实验表明,p38MAPK 抑制剂 SB203580(5-10μg,脑室内注射)和钙泊三醇 C 的给药可产生抗抑郁样表型,而不改变自发运动活动。在暴露于 FST 的动物的前额叶皮层中观察到 JNK 的强烈磷酸化,这种作用在急性给予阿米替林后进一步增强。在阿米替林处理的小鼠的海马体和前额叶皮层中未观察到 cAMP 反应元件结合蛋白(CREB)磷酸化和表达的调节。目前的结果表明,在 FST 暴露的小鼠中,急性给予阿米替林后,PKCɛ 和 p38MAPK 的磷酸化选择性调节,鉴定出 PKCɛ/p38MAPK 信号级联是阿米替林急性抗抑郁样活性的必要步骤。我们还证明了阿米替林在前额叶皮层中 JNK 磷酸化的增强,这可能代表了抗抑郁特性的负调节途径。本文是题为“焦虑和抑郁”的特刊的一部分。